Basic Information
| LncRNA/CircRNA Name | CADM1-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray , qRT-PCR , Western blot , in vitro knockdown etc. |
| Sample | HCC cell lines (HepG2, BEL-7702 and Huh-7) ,normal liver LO2 cell line |
| Expression Pattern | down-regulated |
| Function Description | CADM1-AS1 expression was reduced in HCC.Clinical data showed that this downregulation was associated with advanced tumor stage, high TNM stage and reduced survival in HCC patients.CADM1-AS1 overexpression inhibited HCC cells proliferation, migration and invasion, while inducing G0/G1 phase arrest.CADM1-AS1 inhibited the phosphorylation of AKT and GSK-3?.CADM1-AS1 decreased the cell cycle associated proteins expression of cyclinD, cyclinE, CDK2 CDK4, CDK6, and enhanced the levels of p15, p21 and p27.SC79, a specific activator for AKT;, apparently attenuated the effects of CADM1-AS1 on above cell-cycle associated proteins, confirming that CADM1-AS1 inhibited cell cycles through the AKT signaling pathway.CADM1-AS1 has antitumor effect in vivo by a xenograft HCC mouse model. |
| Pubmed ID | 31118799 |
| Year | 2019 |
| Title | lncRNA CADM1-AS1 Inhibits Cell-Cycle Progression and Invasion via PTEN/AKT/GSK-3? Axis in Hepatocellular Carcinoma |
External Links
| Links for CADM1-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |